Rapidly Progressing Early Puberty in a Boy with Bilateral Basal Ganglia Germinoma and TREX1 Variant

Jihyun Ha, Seonkyeong Rhie, Kyu Young Chae, Eun-Gyong Yoo, Hye Jeong Choi, Go Hun Seo and Mo Kyung Jung

1Department of Pediatrics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea
2Department of Radiology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea
33billion, Inc., Seoul, South Korea

*Corresponding author: Department of Pediatrics, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea. Tel: +82-317801999, Email: Email: mokyung@chamc.co.kr

Received 2020 May 16; Revised 2020 August 10; Accepted 2020 August 18.

Abstract

Introduction: Organic lesions, including brain tumors, should be suspected in boys with precocious puberty. However, it is not usually suspected in children with early puberty.

Case Presentation: Here we present an extremely rare case of rapidly progressing early puberty with basal ganglia germinoma coupled with three-prime repair exonuclease 1 (TREX1) variant. This was a 10-year-old-boy with borderline mental retardation and rapidly progressing puberty. Physical examination revealed 10 mL testes (Tanner stage 3 for genital development), and his bone age was that of a 12-year old boy. Laboratory findings showed abnormally elevated serum β-human chorionic gonadotropin (23.0 mIU/mL; reference, 0-10 mIU/mL), and suppressed LH level (<0.07 mIU/mL) with high testosterone (4.61 ng/mL; reference, 0.1-0.32 ng/mL). Magnetic resonance imaging revealed irregular enhancement in bilateral basal ganglia, and stereotactic biopsy confirmed germinoma. Whole exome sequencing was performed, and the pathogenic variant of TREX1 (TREX1:c.G832A) was revealed.

Conclusions: This is the first case report of rapidly progressing early puberty caused by germinoma of bilateral basal ganglia associated with pathogenic variant of TREX1.

Keywords: Precocious Puberty, Basal Ganglia, Germinoma, Three Prime Repair Exonuclease 1 (TREX1)

1. Introduction

Precocious puberty can be defined as the appearance of secondary sexual characteristics occurring earlier than two standard deviations of the population mean. It can be classified into gonadotropin-dependent (central) and gonadotropin-independent (peripheral) puberty. The majority of central precocious puberty (CPP) is idiopathic, but organic lesions of the central nervous system, such as brain tumors, are more often discovered in boys than in girls. There are many etiologies of peripheral precocious puberty (PPP), such as hormone-secreting tumors, and exogenous hormone exposure (1). Organic lesions including brain tumors should be suspected in boys with precocious puberty, but organic brain lesion is not usually suspected in children with early puberty.

Germinomas are the most common cause of all germ cell tumors (GCTs), and the clinical manifestations depend on their locations, including hemiparesis, diabetes insipidus, and precocious puberty. Intracranial germinomas are exceedingly rare and account for only 0.5 - 2.1% of all primary brain tumors. GCTs of the central nervous system (CNS) usually develop in the midline of the pineal and suprasellar regions. Approximately 5% to 10% of intracranial germinomas can also occur in the basal ganglia and/or thalamus (2), but involvement of both sides of the basal ganglia by germinoma is extremely rare.

Mutations in the three-prime repair exonuclease 1 (TREX1) usually decrease or abolish exonuclease function. These are known to be associated with Aicardi-Gouitières syndrome, systemic lupus erythematosus, and familial chilblain lupus (3, 4). Recently, several studies have reported the association between TREX1 and carcinogenesis in gastric cancer and cervical cancer (5, 6).

In this case, we present a 10-year-old-boy with rapidly progressing early puberty associated with basal ganglia germinoma.
2. Case Presentation

A 10-year-old boy with borderline mental retardation visited our pediatric endocrinology clinic for rapidly progressing pubertal symptoms which had suddenly begun two months before visiting the clinic. The patient had no specific perinatal or family history. Physical examination revealed 10 mL testes and about 6 cm penis (Tanner stage 3 for genital development) as well as left microtia. The height and weight placed him in the 75 - 85th percentile (143.3 cm) and 50 - 75th percentile (38.9 kg), respectively, for his age and sex. He showed impaired speech fluency and distractibility. Neurological examination showed right-sided weakness of the body with hyperreflexia. The cerebellar function test was found to be abnormal on the right side.

Hormonal studies were performed. A markedly elevated level of serum testosterone (4.61 ng/mL; reference, 0.1 - 0.32 ng/mL), with an elevation of luteinizing hormone (LH) levels (< 0.07 mIU/mL), was observed with abnormally elevated levels of serum β-human chorionic gonadotropin (β-hCG, 23.0 mIU/mL; reference, 0 - 10 mIU/mL). Other tumor markers, including α-fetoprotein (AFP) and carcinoembryonic antigen (CEA), were not elevated. Bone age according to Greulich and Pyle method (7) was advanced up to 12 years of age. Gonadotropin-releasing hormone (GnRH) stimulation test was performed. The result showed completely suppressed LH levels (LH peak < 0.07 mIU/mL) with high testosterone levels (6.47 ng/mL; reference, 0.1 - 0.32 ng/mL), without an elevation of luteinizing hormone (LH) levels (< 0.07 mIU/mL), was observed with abnormally elevated levels of serum β-human chorionic gonadotropin (β-hCG, 23.0 mIU/mL; reference, 0 - 10 mIU/mL). Other tumor markers, including α-fetoprotein (AFP) and carcinoembryonic antigen (CEA), were not elevated. Bone age according to Greulich and Pyle method (7) was advanced up to 12 years of age. Gonadotropin-releasing hormone (GnRH) stimulation test was performed. The result showed completely suppressed LH levels (LH peak < 0.07 mIU/mL) with high testosterone levels (6.47 ng/mL; reference, 0.1 - 0.32 ng/mL), without an elevation of luteinizing hormone (LH) levels (< 0.07 mIU/mL), was observed with abnormally elevated levels of serum β-human chorionic gonadotropin (β-hCG, 23.0 mIU/mL; reference, 0 - 10 mIU/mL). Other tumor markers, including α-fetoprotein (AFP) and carcinoembryonic antigen (CEA), were not elevated. Bone age according to Greulich and Pyle method (7) was advanced up to 12 years of age. Gonadotropin-releasing hormone (GnRH) stimulation test was performed. The result showed completely suppressed LH levels (LH peak < 0.07 mIU/mL) with high testosterone levels (6.47 ng/mL; reference, 0.1 - 0.32 ng/mL), without an elevation of luteinizing hormone (LH) levels (< 0.07 mIU/mL), was observed with abnormally elevated levels of serum β-human chorionic gonadotropin (β-hCG, 23.0 mIU/mL; reference, 0 - 10 mIU/mL). Other tumor markers, including α-fetoprotein (AFP) and carcinoembryonic antigen (CEA), were not elevated. Bone age according to Greulich and Pyle method (7) was advanced up to 12 years of age. Gonadotropin-releasing hormone (GnRH) stimulation test was performed. The result showed completely suppressed LH levels (LH peak < 0.07 mIU/mL) with high testosterone levels (6.47 ng/mL; reference, 0.1 - 0.32 ng/mL), without an elevation of luteinizing hormone (LH) levels (< 0.07 mIU/mL), was observed with abnormally elevated levels of serum β-human chorionic gonadotropin (β-hCG, 23.0 mIU/mL; reference, 0 - 10 mIU/mL). Other tumor markers, including α-fetoprotein (AFP) and carcinoembryonic antigen (CEA), were not elevated.

A stereotactic biopsy was conducted and a germinoma was confirmed. The patient received three cycles of combination chemotherapy, consisting of etoposide, carboplatin, and 72 Gy of radiation therapy.

Despite notably decreased tumor lesions after treatment, his pubertal symptoms continued to progress rapidly. After 6 months, at the age of 10.5 years, his bone age was advanced up to 13 years of age. The peak LH level was elevated to 17 mIU/mL in the GnRH stimulation test (Table 1). Gonadotropin-releasing hormone agonist (GnRHa, triptorelin 3.75 mg, every 4 weeks) treatment was started due to begin of central puberty.

The patient complained of lethargy, general weakness, and loss of appetite, moreover, low blood pressure (85/50 mmHg) was observed. Combined pituitary function tests were performed to assess pituitary function, but all anterior pituitary hormones showed normal response (basal cortisol: 10.8 µg/dl, peak cortisol: 20.2 µg/dl). His echocardiogram was normal. He started to take hydrocortisone 5 - 10 mg for body surface area due to clinical suspicion of adrenal insufficiency, and symptoms seemed to be improved. The GnRHa treatment was maintained for one year and discontinued at 14 years of his bone age.

He was followed up regularly for two years without any sign of recurrence. However, his height measured 152.1 cm (25 - 50th percentile) and the height for his BA was far below the 3rd percentile.

Due to an unusual type of intracranial germinoma with mental retardation, whole exome sequencing (WES) was performed and the pathogenic variant of TREX1 was revealed. This variant was confirmed by Sanger sequencing (Figure 1D). It showed the heterozygous variant c.G832A on TREX1 changes an amino acid Ala to Thr at codon 278 in exon 1 (TREX1:c.G832A). Based on American College of Medical Genetics and Genomics (ACMG) guidelines, this variation has one strong, two moderate, and two supporting levels of evidence (https://omim.org/entry/6066609/). This variant changes the Ribonuclease H-like domain (https://www.uniprot.org/uniprot/Q9NSU2/) without benign variation, and is absent in controls (https://www.internationalgenome.org/, https://gnomad.broadinstitute.org/), with multiple lines of computational evidence of gene product; MetaSVM (https://omictools.com/meta-svm-tool/), GERP++ (https://omictools.com/gerp-tool/). In silico analysis revealed that, the missense variant in TREX1 c.832G>A, p.A278T was likely to be a damaging variant (score 0.997) as per Polyphen-2 (8) (Figure 1E) and damaging based on SIFT (score 0.020, cut off 0.05) (https://sift.bii.a-star.edu.sg/). Splice-site analysis showed variable results. Net gene 2 (https://www.ncbi.nlm.nih.gov/clinvar/1506628/) and Splice site prediction showed no change in the splicing site (https://fruitfly.org/seq_tools/splice.html), but Mutation Taster (http://www.mutationtaster.org/) showed changes in the splicing site (score 0.36).

Method for Whole Exome Sequencing (WES)

A buccal swab sample was obtained from the patient to extract genomic DNA. WES was performed using SureSelect Human All Exon V6 (Agilent, Santa Clara, CA, USA), following the manufacturer’s protocol, followed by sequencing using the NovaSeq platform (Illumina, San Diego, California).
Table 1. The Characteristics and Hormone Levels of Patient with Basal Ganglia Germinoma Before and After Treatment (Chemotherapy and Radiation Therapy)

| Characteristics                  | Before Treatment | After Treatment |
|----------------------------------|-----------------|-----------------|
| Chronologic age (y)              | 10              | 10.5            |
| Height (cm)                      | 143.3 (75 - 85th percentile) | 149.5 (85 - 90th percentile) |
| Weight (kg)                      | 38.9 (50 - 75th percentile) | 36.0 (25 - 50th percentile) |
| Bone age (y)                     | 12              | 13              |
| Basal LH (mIU/mL)                | < 0.07          | 1.18            |
| LH peak in GnRH stimulation (mIU/mL) | < 0.07       | 17.03           |
| Basal FSH (mIU/mL)               | < 0.30          | 2.80            |
| FSH peak in GnRH stimulation (mIU/mL) | 1.85          | 6.82            |
| Testosterone (ng/mL)             | 4.61            | 0.59            |

Abbreviations: LH, luteinizing hormone; FSH, follicle-stimulating hormone; GnRH, gonadotropin-releasing hormone.

USA). Mean depth of coverage was $100 \times (>10 \times =99.2\%)$. Pathogenicity of each variant for associated disease was evaluated according to recommendations of the ACMG and Association for Molecular Pathology (AMP) guidelines (9).

3. Discussion

In this case, we reported an extremely rare case of bilateral basal ganglia germinoma in a boy with TREX1 variant, which presented with rapidly progressing early puberty.

Germinomas account for approximately two-thirds of GCTs and usually develop in the midline at the pineal and suprasellar regions. However, they may arise from an ectopic site, most notably the basal ganglia and thalamus, which is extremely rare. Interestingly, intracranial germinoma involving basal ganglia occurs predominantly in Eastern Asian countries, including Japan, with a male predominance (10).

The clinical manifestations of germinoma can vary, depending on its locations. Takeda et al. (2) studied 109 patients with basal ganglia germinoma, and hemiparesis was the most common symptom. Other symptoms were change of character, mental retardation, precocious puberty, and diabetes insipidus. Furthermore, precocious puberty can be the sole clinical manifestation. Since $\beta$-hCG and LH possess an identical $\alpha$-subunit and a similar $\beta$-subunit, the secretion of $\beta$-hCG can stimulate Leydig cells to induce precocious puberty (11). These clinical symptoms are usually known to progress slowly, with an average period of about 1.5 years, ranging from one month to 4.5 years. In our case, hemiparesis seemed to have progressed similar to other germinomas, but the patient’s pubertal symptom was rapidly progressive within two months.

**TREX1** is the major cytoplasmic 3’-5’ DNA exonuclease in mammalian cells (12). **TREX1** mutations usually decrease or abolish exonuclease function. These are known to be associated with neurologic or autoimmune diseases such as Aicardi-Gouitères syndrome, systemic lupus erythematosus, and familial chilblain lupus (3, 4). Recently, several studies have reported the association between the **TREX1** and tumorigenesis. Prati et al. (6) indicated that **TREX1** up-regulation was an important factor for the growth of cervical tumor cells and may contribute to tumor progression. Also, malfunction of DNA mismatch repair genes, including **TREX1**, has been reported to be associated with a risk of gastric cancer by causing microsatellite instability (5). Vanpouille-Box et al. (13) identified **TREX1** as a key determinant for the limited immunogenicity of cancer cells responding to single high-dose radiation. The role of **TREX1** in carcinogenesis is still unclear, but recent studies have shown that the alteration of **TREX1**, which is essential for DNA damage repair and elimination of cytoplasmic DNA, consequently preventing the activation of innate immune mechanisms, may lead to cancer development (6).

The pathogenesis and underlying genetic abnormalities of CNS germinoma are not well known. Recent case reports of germinoma in the CNS associated with chromosomal abnormalities include Down syndrome (14) and Klinefelter syndrome (15). In a genome-wide analysis in 49 cases of CNS germinomas, it was reported that CNS germinomas were characterized by global demethylation, chromosomal instability, and mutational activation of the Kit-, Ras/Raf/Erk- and Akt-pathways (16). To our knowledge, this is the first case of germinoma associated with the **TREX1**.

Germinoma is highly sensitive to radiotherapy and/or chemotherapy and is potentially curable without surgery, leading to a good prognosis and high chance of long-term
Ha J et al.

Figure 1. A-C, Sella magnetic resonance imaging of the patient with basal ganglia germinoma showing rapidly progressing early puberty (high signal intensity lesions were marked as arrows); A, T1-weighted image. B, T2-weighted image. C, Midline sagittal view. D, Sanger sequencing of the patient with basal ganglia germinoma coupled with TREX1 variant; E, In silico analysis of the missense variants of TREX1 A278T in the patient survival. However, early diagnosis of basal ganglia germinoma is usually difficult, owing to its rare location and nonspecific symptoms. If the diagnosis is delayed, the disease can become disseminated and may result in permanent neurological deficits.

Organic CNS causes of precocious precocity should be ruled out by brain MRI. Brain MRI is usually recommended in girls under 6 years of age and all boys with CPP to exclude pathological brain lesions, but specific criteria for performing brain imaging are still lacking (1). However, this patient is thought to be an exceptional case, although the underlying cause of early puberty is usually idiopathic. Therefore, even in patients with rapidly progressing early puberty, hormonal and imaging studies could be conducted.

The limitation of this report is that there was neither an in vitro nor functional study to support that this variant is pathogenic. Furthermore, the trio-test for family was not conducted to find de novo mutation in patients.

In conclusion, we present an extremely rare case of bi-
lateral basal ganglia germinoma associated with the TREX1. Further studies are needed to identify the pathogenic genes of germinoma, including TREX1.

Footnotes

Authors’ Contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Conflict of Interests: The authors have no conflicts of interest to disclose.

Ethical Approval: This study was approved by the Institutional Review Board (IRB) of Bundang CHA Medical Center (No. 2018-2-00861, Intelligent SW Technology Development for Information & communications Technology Promotion (IITP) grant funded by the Korea government (MSIT) for Information & communications Technology Promotion). Written informed consent was obtained from the patient and his parents for the publication of this report.

Informed Consent: Written informed consent was obtained from the patient and his parents for the publication of this report.

References

1. Kliewe R, Stanton B, Gene J, Schor N, Behrman R. Nelson Textbook of Pediatrics. New York: Elsevier Health Sciences; 2015.
2. Takeda N, Fujita K, Katayama S, Uchiyama Y, Okamura Y, Nigami H, et al. Germinoma of the basal ganglia. An 8-year asymptomatic history after detection of abnormality on CT. Pediatr Neurosurg. 2004;40(6):306-11. doi: 10.1159/0000813745. [PubMed: 15821363].
3. Lee-Kirsch MA, Chowdhury D, Harvey S, Gong M, Senenko L, Engel K, et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med (Berl). 2007;85(5):531-7. doi: 10.1002/smmj.200700999. [PubMed: 17440703].
4. Lee-Kirsch MA, Wolf C, Gunther C. Aicardi-Goutieres syndrome: a model disease for systemic autoimmunity. Clin Exp Immunol. 2014;175(1):17-24. doi: 10.1111/cei.12160. [PubMed: 23786362]. [PubMed Central: PMC3898550].
5. Zhu H, Li X, Zhang X, Chen D, Li D, Ren J, et al. Polymorphisms in mismatch repair genes are associated with risk and microsatellite instability of gastric cancer, and interact with life exposures. Gene. 2016;579(1):52-7. doi: 10.1016/j.gene.2015.12.050. [PubMed: 26724419].
6. Prati B, da Silva Abjaude W, Terminl I, Morale M, Herbster S, Longatto-Filho A, et al. Three prime repair exnuclease 1 (TREX1) expression correlates with cervical cancer cells growth in vitro and disease progression in vivo. Sci Rep. 2019;9(1):3351. doi: 10.1038/s41598-018-37064-x. [PubMed: 30674977]. [PubMed Central: PMC6344463].
7. Greulich WW, Pyle S. Radiographic atlas of skeletal development of the hand and wrist. Am J Med Sci. 1959;238(3):393. doi: 10.1097/00000444-195909000-00030.
8. Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet. 2013;76(1):7.20.1-7.20.41. doi: 10.1002/9780471142905.hg0720s76. [PubMed: 23135928]. [PubMed Central: PMC4480630].
9. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(7):405-24. doi: 10.1038/gim.2015.30. [PubMed: 25748688]. [PubMed Central: PMC4544751].
10. Echevarria ME, Fanguasaro J, Goldman S. Pediatric central nervous system germ cell tumors: a review. Oncologist. 2008;13(6):690-9. doi: 10.1634/theoncologist.2008-0037. [PubMed: 18589244].
11. Schneider DT, Calaminus G, Gobel U. Diagnostic value of alpha f-fetoprotein and beta-human chorionic gonadotropin in infancy and childhood. Pediatr Hematol Oncol. 2006;23(1):11-26. doi: 10.1080/08880010500959828. [PubMed: 16203836].
12. Yang YG, Lindahl T, Barnes DE. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell. 2007;131(5):873-86. doi: 10.1016/j.cell.2007.07.017. [PubMed: 18045531].
13. Vanpouille-Box C, Alard A, Aryankalayil MJ, Sarfraz Y, Diamond M, Schneider RJ, et al. DNA exonuclease Trex regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15616. doi: 10.1038/ncomms15616. [PubMed: 28594845]. [PubMed Central: PMC5472575].
14. Nakashima T, Nishimura Y, Sakai N, Yamada H, Hara A. Germinoma in cerebral hemisphere associated with Down syndrome. Childs Nerv Syst. 1997;13(10):563-6. doi: 10.1007/s003810050139. [PubMed: 9403208].
15. Nakata Y, Yagishita A, Arai N. Two patients with intraspinal germinoma associated with Klenefelter syndrome: case report and review of the literature. AJNR Am J Neuroradiol. 2006;27(3):620-4. [PubMed: 16752654].
16. Schulte SI, Waha A, Steiger B, Denkhaus D, Dornier E, Calaminus G, et al. CNS germinomas are characterized by global demethylation, chromosomal instability and mutational activation of the KIt, Ras/Raf/Erk- and Akt-pathways. Oncotarget. 2016;7(34):55026-42. doi: 10.18632/oncotarget.10392. [PubMed: 27391550]. [PubMed Central: PMC5423999].